The Need to Define Treatment Goals for Protein-Losing Enteropathy in Fontan Care and Research

We read with interest the recent paper by Itkin et al. [(1)][1]. The authors are to be commended for their effort. However, the results should be viewed in the context of specific limitations. First, the serum albumin level is frequently being used as a surrogate endpoint in Fontan patients with